Parental Opioid Use Disorders Market Size (2023 – 2030)

The Global Parental Opioid Use Disorders (OUD) Market was estimated to be worth USD 1.94 Billion in 2022 and is projected to reach a value of USD 3.59 Billion by 2030, growing at a CAGR of 8% during the forecast period 2023-2030.

One or both parents of a kid must have an opioid addiction in order for there to be parental opioid use disorder (OUD). The child's health and well-being may be seriously harmed by this sickness. Recent years have seen a sharp rise in the prevalence of parental OUD, fuelling a booming industry for products and services designed to address the issue. Opioids are the most often abused drugs and an estimated 8 million children in the United States live with at least one parent who has a substance use disorder, according to a Wiley study. These children face a number of challenges, including an increased risk of abuse and neglect, poor academic performance, and social and emotional difficulties. Due to the urgent need to meet the unique needs of the affected children and families as well as the rising prevalence of OUD, there is a rapid growth in the demand for parental OUD therapies. Integrated care models and the use of digital technology to enhance access to treatment are two hopeful trends, despite the fact that there are still many issues that need to be resolved, such as stigma and the need for further research. There will be a larger need for efficient and thorough therapy for parental OUD as long as the opioid epidemic has a detrimental influence on communities across the nation.

Global Parental Opioid Use Disorders (OUD) Market Drivers:

The increasing prevalence of Parental Opioid Use Disorders (OUD) is boosting market growth.

One of the key elements affecting the global market for parental OUD is the condition's rising prevalence. The opioid pandemic has increased the likelihood of OUD in particular for parents of young children, according to the Centers for Disease Control and Prevention (CDC). In addition to support services, children and families affected by parental OUD now need more in-depth and effective therapy. Parental OUD has become more prevalent due to a variety of reasons, including opioid overprescribing, the ease with which one can obtain illegal opioids, and the high likelihood of relapse among those completing treatment. The need for medicines that can effectively treat OUD and address its root causes is growing driving the market growth as well.

The growing awareness of the Impact of Parental Substance Abuse on Children is driving market growth.

The increased understanding of the effects of parental substance misuse on children is another important factor driving the global market for parental OUD. According to research, children of OUD parents are more likely to experience a variety of adverse consequences, such as abuse and neglect, low academic performance, mental health problems, and substance misuse. The emphasis on providing comprehensive care for families affected by parental OUD has expanded as a result of this raised awareness. Along with support services that cater to the particular needs of kids and families, such as parenting classes, family therapy, and peer support groups, this also consists of clinical treatments for OUD.

Global Parental Opioid Use Disorders (OUD) Market Challenges:

One of the main problems the worldwide parental OUD market is facing right now is the stigma attached to drug use. People with drug abuse disorders frequently experience prejudice and hostility from co-workers, medical experts, and the general public, despite the fact that OUD is a chronic medical disease. This stigma may make it difficult for parents with OUD to seek treatment, which may have an impact on the standard of care they receive. It may be difficult to recruit and retain qualified healthcare practitioners who are adept in providing OUD therapies that are supported by evidence because of the stigma associated with substance addiction. This stigma needs to be removed if outcomes for OUD patients and their families are to improve.

Global Parental Opioid Use Disorders (OUD) Market Opportunities:

The ongoing enhancements in treatment choices provide a significant market opportunity for parents with OUD worldwide. There has been substantial advancement in the creation of new and efficient OUD treatments recently, consisting of telemedicine, behavioural therapy, and medication-assisted treatment (MAT). These improvements in treatment options have the potential to better the lives of people with OUD and their families while addressing market issues like stigma and care access. To take advantage of this potential, more funding must be committed to research and the creation of innovative interventions and therapies. 

COVID-19 Impact on Global Parental Opioid Use Disorders (OUD) Market:

The expanded usage of telemedicine brought about by COVID-19 will help the global market for parental OUDs. As a result of the pandemic, telemedicine services have risen quickly, allowing OUD patients to get therapy remotely and lower their chance of catching COVID-19. The outbreak has hurt the global market for parental OUDs, though. Due to the disruption of treatment and support services brought on by COVID-19, providing comprehensive care for families affected by OUD has proven to be difficult. Stress and financial uncertainty have increased as a result of the economic effects of the outbreak, which can exacerbate substance misuse and other mental health problems.

Global Parental Opioid Use Disorders (OUD) Market Recent Developments:

• In March 2022, Collegium Pharmaceutical completed the acquisition of BioDelivery Sciences International. The move is part of Collegium's goal to become a top specialty pharmaceutical company.

• In December 2020, Orexo AB signed an exclusive licensing agreement with Accord Healthcare for the commercialisation of ZUBSOLV® in Europe.

PARENTAL OPIOID USE DISORDERS MARKET REPORT COVERAGE:

Global Parental Opioid Use Disorders (OUD) Market Segmentation: By Drug Class

• Methadone

• Naltrexone

• Buprenorphine

Buprenorphine, methadone, and naltrexone are the three medication classes that can be used to segment the global market for parental OUD. Due to its effectiveness in lowering withdrawal symptoms and cravings and lesser risk for abuse compared to other opioids, buprenorphine is the most frequently prescribed drug for the treatment of OUD and commands the biggest market share. Although methadone is frequently administered in tightly controlled clinics because of the risk of overdose, it is also frequently used to treat OUD. Because of its reduced efficacy and high likelihood of relapse, naltrexone, which blocks the effects of opioids, is less frequently used. Nevertheless, because of its low potential for abuse and the availability of newer, longer-acting formulations, the market for naltrexone is predicted to expand. Due to its well-established efficacy and safety profile, the buprenorphine segment is anticipated to maintain its dominant market position overall. On the other hand, the naltrexone segment is anticipated to expand as more people become aware of its advantages.

Global Parental Opioid Use Disorders (OUD) Market Segmentation: By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies & Stores

• Online Pharmacies

• Others

Hospital pharmacies, retail pharmacies & stores, and online pharmacies are additional distribution channel categories that can be used to segment the global parental OUD market. Due to their function as the principal supplier of OUD treatment, particularly for severe cases, hospital pharmacists control the majority of the market share. Retail pharmacies and stores provide as convenient and accessible distribution routes for people who need ongoing treatment for OUD. Although online pharmacies are a relatively new form of distribution, their market share is anticipated to increase as a result of their capacity to provide convenience and discretion for patients who might experience stigma or other obstacles to receiving care. As more people look for remote access to care, the COVID-19 pandemic has also accelerated the adoption of online pharmacies for OUD treatment. Overall, hospital pharmacies are anticipated to maintain their dominant market position; however, the market for online pharmacies is anticipated to expand as a result of shifting patient preferences and the expansion of telemedicine services.  

Global Parental Opioid Use Disorders (OUD) Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East & Africa

North America, Europe, Asia Pacific, South America, and the Middle East & Africa are further regions into which the global parental OUD market can be divided. Due to the high prevalence of opioid use and the accessibility of well-established OUD treatment programs, such as medication-assisted treatment and counselling services, North America now maintains the greatest market share. Due to the high incidence of opioid use in various nations and the availability of complete healthcare systems, Europe is also a sizable market for the treatment of parental OUD. The Asia Pacific market is anticipated to expand quickly, propelled by rising opioid usage rates and the deployment of new treatment initiatives in nations like China and India. Despite being smaller, the Middle East, Africa, and South American markets are anticipated to grow as more people become aware of the advantages of OUD treatment and new laws and programs are put in place to combat opioid use. Overall, North America is anticipated to maintain its dominant market position, while the Asia Pacific region is anticipated to see the fastest market growth due to demographic and regulatory considerations. 

Global Parental Opioid Use Disorders (OUD) Market Key Players:

1. Indivior PLC (U.S.)

2. Alkermes (Ireland)

3. Orexo AB (Sweden)

4. Titan Pharmaceuticals, Inc. (U.S.)

5. Mallinckrodt Pharmaceuticals (U.K.)

6. BioDelivery Sciences International Inc. (U.S.)

7. Viatris Inc. (Mylan N.V.) (U.S.)

8. Hikma Pharmaceuticals PLC (U.K.)

9. Camurus (Sweden)

10.